Compare MFA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFA | ANL |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.0M | 998.8M |
| IPO Year | 1998 | 2022 |
| Metric | MFA | ANL |
|---|---|---|
| Price | $5.78 | $10.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $12.58 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 2.8M | 268.1K |
| Earning Date | 11-04-2026 | 08-14-2026 |
| Dividend Yield | ★ 25.90% | N/A |
| EPS Growth | ★ 58.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $243.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.55 | $0.88 |
| 52 Week High | $10.43 | $17.25 |
| Indicator | MFA | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 27.56 | 46.74 |
| Support Level | N/A | $8.95 |
| Resistance Level | $6.87 | $11.90 |
| Average True Range (ATR) | 0.24 | 0.99 |
| MACD | -0.05 | 0.25 |
| Stochastic Oscillator | 18.35 | 72.55 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets; and Lima One.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.